NMNAT1 polyclonal (C-Term), anti-human

Background:
Catalyzes the formation of NAD(+) from nicotinamide mononucleotide (NMN) and ATP. Can also use the deamidated form; nicotinic acid mononucleotide (NaMN) as substrate with the same efficiency. Can use triazofurin monophosphate (TrMP) as substrate. Also catalyzes the reverse reaction, i.e. the pyrophosphorolytic cleavage of NAD(+). For the pyrophosphorolytic activity, prefers NAD(+) and NAAD as substrates and degrades NADH, nicotinic acid adenine dinucleotide phosphate (NHD) and nicotinamide guanine dinucleotide (NGD) less effectively. Fails to cleave phosphorylated dinucleotides NADP(+), NADPH and NAADP(+). Protects against axonal degeneration following mechanical or toxic insults.

Other Names:
Nicotinamide mononucleotide adenylyltransferase 1, NMN adenylyltransferase 1, 2.7.7.1, Nicotinate-nucleotide adenylyltransferase 1, NaMN adenylyltransferase 1, 2.7.7.18, NMNAT1, NMNAT

Target/Specificity:
This NMNAT1 antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 171-201 amino acids from human NMNAT1.

Antigen Type: Synthesized Peptide

Gene Name: NMNAT1 (HGNC:17877)
Gene ID: 64802
Primary Accession: Q9HAN9
Other Accession: Q0VD50
Format: Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.